Recent 8-K filings for FATE

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 13, 2026 12:32 UTC earnings item 2.02item 9.01

  Fate Therapeutics Q1 2026: $174.8M cash, $1.3M revenue; FT819 lupus trial on track

source · FATE on sec.gov